STEVENSON, Md., Dec. 04, 2017 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of Ohio on behalf of purchasers of Meridian Bioscience, Inc. (NASDAQ:VIVO) (“Meridian” or the “Company”) securities during the period between March 25, 2016 and July 13, 2017, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until January 16, 2018 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Meridian securities during the Class Period. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that Meridian’s lead tests provide inaccurate results.
According to the complaint, following a May 17, 2017 press release by the U.S. Food and Drug Administration (“FDA”) warning about the inaccuracy of the Company’s lead tests, and a July 13, 2017 statement by the FDA regarding the status of the investigation into the inaccurate results, the value of Meridian shares declined significantly.
If you have suffered a loss in excess of $100,000 from investment in Meridian securities purchased on or after March 25, 2016 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/casesandinvestigations.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
[email protected]


Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Washington Post Publisher Will Lewis Steps Down After Layoffs
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 



